The main point is that name drugs empowered for rare diseases utilize our specialized Orphan-named intelligence program.
The basic idea is that 7K+ rare diseases with 50K+ passed drugs with orphan identification authorization, natural history data and consolidation of patient registers.
Rare diseases, common drugs.
See Platform DocumentationFDA, EMA, 50+ countries orphan designations mapped.
In simple terms, psychoanalysis of exclusion periods, prevalence limens and identification criteria for the fastest regulatory footpaths.
Explore Orphan DataHPO terms, OMIM phenotypes computationally matched.
An important finding is that semantic similarity identifies drugs modulating phenotypes or similar footpaths for common diseases practice to rare indications.
View Phenotype Matching100+ registries with 1M+ rare disease patients.
Basically, clinical trial solvents, treatment exposures and genotype-phenotype correlations support the survival of clinical surveys and evaluation criteria.
Learn About Registries